Skip to main content

Table 5 QALY (quality-adjusted life-year) accrual associated with the three cohorts over 9 years (discounted at 3 % annually)

From: Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

Model

TTZ cohort

TT cohort

Control cohort [25]

First-eye model

7.202

7.050

6.749

Second-eye model

5.269

5.016

4.616

Combined-eye model

6.546

6.384

6.024

  1. TTZ triple therapy with zeaxanthin, TT triple therapy
  2. Combined-eye model = 66 % first-eye model and 34 % second-eye model, Zeaxanthin = Zx
Back to article page

International Journal of Retina and Vitreous

ISSN: 2056-9920

Contact us